Pfizer partners with healthtech company on AI-powered cardiovascular disease detection

Related Articles
Anumana expands AI cardiac care platform with support from Boston Scientific
MassDevice: Anumana announced today that it brought its diagnostic ECG-AI technology into perioperative and acute cardiac care with help from Boston Scientific.April 24, 2025
Anumana wins FDA breakthrough nod for AI algorithm that detects pulmonary hypertension
Mass Device: Anumana announced today that it received FDA breakthrough device designation for its pulmonary hypertension (PH) early detection algorithm. Cambridge, Massachusetts-based Anumana, formed by Mayo Clinic and nference and launched in…May 23, 2022
AI specialists ink deal with Pfizer to target cardiac amyloidosis
Cardiovascular Business: Anumana, a Massachusetts-based healthcare technology company focused on artificial intelligence (AI), has announced a new multi-year deal with Pfizer focused on improving the identification and diagnosis of cardiac…December 20, 2022
Pfizer links up with heart disease AI developer Anumana to build cardiac amyloidosis diagnostics
FIERCE Biotech: The heart-focused artificial intelligence company Anumana is looking to break new ground for its algorithms through a partnership with Pfizer. They plan to develop programs that can help…December 16, 2022


